 WATERTOWN, Mass., Jan. 06, 2021 GLOBE NEWSWIRE -- Aileron Therapeutics, Inc. Nasdaq: ALRN, today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 32,630,983 of its shares of common stock at a purchase price of 1.10 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about January 8, 2021, subject to the satisfaction of customary closing conditions. 